Eli Lilly and Company (LLY) 81.29 $LLY
Global Musculoskeletal Disorders Therapeutics Market 2016-2020 with AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche & Eli Lilly Dominating - Research and Markets
BusinessWire - Wed Sep 21, 9:19AM CDT
Research and Markets has announced the addition of the "Global Musculoskeletal Disorders Therapeutics Market 2016-2020" report to their offering.
JNJ: 119.46 (+0.55), AMGN: 175.62 (+1.77), LLY: 81.29 (+0.42)
InvestorsObserver releases covered-call reports for Kinder Morgan, American Airlines, Eli Lilly, Procter & Gamble and Celgene
PR Newswire - Wed Sep 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAL, CELG, KMI, LLY, and PG.
KMI: 22.11 (-0.03), AAL: 35.25 (+0.58), LLY: 81.29 (+0.42), PG: 88.99 (+1.19), CELG: 110.57 (+0.99)
StratusLIVE Online Fundraising Software Reaches Half Million Users in 2016
PRWeb - Tue Sep 20, 12:31PM CDT
StratusLIVE, LLC, a leading provider of cloud-based software serving the nonprofit community, has announced its 2016 user adoption milestones. As enterprise class software, StratusLIVE's adoption of modern responsive design, mobile availability and a robust feature set has resulted in StratusLIVE online fundraising being selected as the technology solution for over 400 corporate social responsibility campaigns, representing more than 500,000 employees.
FITB: 20.80 (+0.06), LLY: 81.29 (+0.42)
Eli Lilly Set to Possibly Pullback After Yesterday's Rally of 1.31%
Comtex SmarTrend(R) - Tue Sep 20, 12:31PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $79.29 to a high of $80.25. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $79.37 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 81.29 (+0.42)
SmarTrend Watching for Potential Pullback in Shares of Eli Lilly After 1.31% Gain
Comtex SmarTrend(R) - Tue Sep 20, 12:29PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $79.29 to a high of $80.25. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $79.37 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 81.29 (+0.42)
Analyzing the Global Diabetes Market 2016 - Leading Players are Takeda, Sanofi, Novo Nordisk, Merck & Co. & Eli Lilly & Co - Research and Markets
BusinessWire - Tue Sep 20, 3:17AM CDT
Research and Markets has announced the addition of the "Analyzing the Global Diabetes Market 2016" report to their offering.
NVO: 45.57 (-0.47), MRK: 63.02 (+0.32), LLY: 81.29 (+0.42)
Eli Lilly's Taltz And Novartis' Cosentyx Introduce Disruption To The Psoriasis Market, According To A New Report From Spherix Global Insights
PR Newswire - Mon Sep 19, 4:26PM CDT
Over 70% of the surveyed dermatologists report that their biologic use has increased over the past year, playing catch up to rheumatologists' use in psoriatic arthritis. On top of this increase, dermatologists are also shifting their mix of various MOAs. Indeed, more than half agree with the statement "I anticipate decreasing my use of TNF-inhibitors and increasing my use of alternative MOAs for the treatment of psoriasis in the near future."
LLY: 81.29 (+0.42)
Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:25AM CDT
Eli Lilly (LLY) announced that the EMA's CHMP issued a positive opinion on olaratumab for the treatment of advanced soft tissue sarcoma (STS).
ANIP: 66.81 (+1.69), LLY: 81.29 (+0.42), CORT: 6.49 (+0.27), PCRX: 37.52 (+0.71)
Research and Markets - Global Insulin Delivery Systems Market 2016-2020 - Key vendors are Novo Nordisk, Sanofi, BD, Eli Lilly & Medtronic
PR Newswire Europe - Sat Sep 17, 6:31AM CDT
DUBLIN, September 2, 2016 /PRNewswire/ --
MDT: 87.82 (+0.68), LLY: 81.29 (+0.42)
Research and Markets - Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating the $150+ Billion Market
PR Newswire Europe - Sat Sep 17, 5:54AM CDT
DUBLIN, August 31, 2016 /PRNewswire/ --
MRK: 63.02 (+0.32), LLY: 81.29 (+0.42)
CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma
PR Newswire - Fri Sep 16, 6:22AM CDT
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the granting of a conditional marketing authorization for olaratumab, in combination with doxorubicin, for the treatment of adults in the European Union (EU) with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and who have not been previously treated with doxorubicin. The CHMP reviewed olaratumab under EMA's accelerated assessment program. If approved, olaratumab will be marketed under the trade name LARTRUVO(TM).
LLY: 81.29 (+0.42)
Boston Mayor Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter, Receive Alzheimer's Readiness Award
PR Newswire - Thu Sep 15, 11:15AM CDT
Boston Mayor Martin J. Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter were recognized today for their efforts to ensure the city of Boston is prepared for the fiscal and social impact of Alzheimer's disease.
LLY: 81.29 (+0.42)
Modality Solutions Announces Partnership with IQPC for the 14th Annual Cold Chain GDP & Temperature Management Logistics Global Forum
PRWeb - Thu Sep 15, 2:49AM CDT
Modality Solutions, LLC, a privately-held company that delivers integrated cold chain management solutions for life sciences and food industries, is pleased to announce they are once again sponsoring and presenting an innovative approach to understanding thermal passive shipper performance at the 14th Annual Cold Chain GDP & Temperature Management Logistics Global Forum. Modality Solutions will be joined by 850 temperature controlled life science leaders, September 26-30 at the Hynes Veterans Memorial Convention Center in Boston, Massachusetts.
LLY: 81.29 (+0.42)
Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career
PR Newswire - Wed Sep 14, 8:30AM CDT
Eli Lilly and Company (NYSE: LLY) today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior vice president, Global Development & Medical Affairs, for Lilly's Oncology business on January 1, 2017. He will succeed Richard Gaynor, M.D., who will retire after a distinguished career at Lilly.
LLY: 81.29 (+0.42)
Elanco's Antibiotic Stewardship Plan Yields Innovation, Scientific Advancements
PR Newswire - Wed Sep 14, 5:00AM CDT
Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), reports on scientific and structural advancements made toward enhancing responsible antibiotic use and bringing new alternatives to decrease the need for shared-class antibiotics in livestock. In an update tracking progress of its 8-Point Antibiotic Stewardship Plan unveiled last year, Elanco announces the following actions:
LLY: 81.29 (+0.42)
2020 Animal Health Market Forecasts: Sanofi, Merck and Co., Eli Lilly and Company & Zoetis Inc. Reviewed
PR Newswire Europe - Wed Sep 14, 1:13AM CDT
PUNE, India, September 14, 2016 /PRNewswire/ --
ZTS: 51.63 (+0.57), MRK: 63.02 (+0.32), LLY: 81.29 (+0.42)
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 8:12AM CDT
Media and political focus on the high prices of drugs have made things difficult for the pharma/biotech sector since the past one year.
ABT: 42.22 (+0.30), BIIB: 314.81 (+2.81), VNDA: 16.62 (+1.06), PFE: 34.15 (-0.13), AMGN: 175.62 (+1.77), AEGR: 2.65 (+0.33), LLY: 81.29 (+0.42), PDLI: 3.35 (-0.01), JNJ: 119.46 (+0.55), GILD: 81.52 (-0.18), AZN: 34.28 (+0.53), MRK: 63.02 (+0.32), SNY: 38.57 (+0.19), NVS: 82.03 (+0.51)
Pharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib
Arpita Dutt - Zacks Investment Research - Fri Sep 09, 7:14AM CDT
The drug pricing controversy and Mylan (MYL) remained in the news this week as well.
AGN: 243.43 (+5.02), NVO: 45.57 (-0.47), MRK: 63.02 (+0.32), MYL: 42.59 (+0.68), LLY: 81.29 (+0.42), BMY: 56.42 (+0.49), SNY: 38.57 (+0.19)
Upgrade Alert for Eli Lilly (LLY)
Comtex SmarTrend(R) - Fri Sep 09, 3:14AM CDT
Eli Lilly (NYSE:LLY) was upgraded from Neutral to Overweight at JP Morgan today. The stock closed yesterday at $79.89 on volume of 4.4 million shares, above average daily volume of 3.5 million. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company's products are sold in countries around the world. Eli Lilly's products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
LLY: 81.29 (+0.42)
Global Musculoskeletal Disorders Therapeutics Market 2016-2020 with AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche & Eli Lilly Dominating - Research and Markets
BusinessWire - Wed Sep 21, 9:19AM CDT
Research and Markets has announced the addition of the "Global Musculoskeletal Disorders Therapeutics Market 2016-2020" report to their offering.
JNJ: 119.46 (+0.55), AMGN: 175.62 (+1.77), LLY: 81.29 (+0.42)
InvestorsObserver releases covered-call reports for Kinder Morgan, American Airlines, Eli Lilly, Procter & Gamble and Celgene
PR Newswire - Wed Sep 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAL, CELG, KMI, LLY, and PG.
KMI: 22.11 (-0.03), AAL: 35.25 (+0.58), LLY: 81.29 (+0.42), PG: 88.99 (+1.19), CELG: 110.57 (+0.99)
StratusLIVE Online Fundraising Software Reaches Half Million Users in 2016
PRWeb - Tue Sep 20, 12:31PM CDT
StratusLIVE, LLC, a leading provider of cloud-based software serving the nonprofit community, has announced its 2016 user adoption milestones. As enterprise class software, StratusLIVE's adoption of modern responsive design, mobile availability and a robust feature set has resulted in StratusLIVE online fundraising being selected as the technology solution for over 400 corporate social responsibility campaigns, representing more than 500,000 employees.
FITB: 20.80 (+0.06), LLY: 81.29 (+0.42)
Eli Lilly Set to Possibly Pullback After Yesterday's Rally of 1.31%
Comtex SmarTrend(R) - Tue Sep 20, 12:31PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $79.29 to a high of $80.25. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $79.37 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 81.29 (+0.42)
SmarTrend Watching for Potential Pullback in Shares of Eli Lilly After 1.31% Gain
Comtex SmarTrend(R) - Tue Sep 20, 12:29PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $79.29 to a high of $80.25. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $79.37 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 81.29 (+0.42)
Analyzing the Global Diabetes Market 2016 - Leading Players are Takeda, Sanofi, Novo Nordisk, Merck & Co. & Eli Lilly & Co - Research and Markets
BusinessWire - Tue Sep 20, 3:17AM CDT
Research and Markets has announced the addition of the "Analyzing the Global Diabetes Market 2016" report to their offering.
NVO: 45.57 (-0.47), MRK: 63.02 (+0.32), LLY: 81.29 (+0.42)
Eli Lilly's Taltz And Novartis' Cosentyx Introduce Disruption To The Psoriasis Market, According To A New Report From Spherix Global Insights
PR Newswire - Mon Sep 19, 4:26PM CDT
Over 70% of the surveyed dermatologists report that their biologic use has increased over the past year, playing catch up to rheumatologists' use in psoriatic arthritis. On top of this increase, dermatologists are also shifting their mix of various MOAs. Indeed, more than half agree with the statement "I anticipate decreasing my use of TNF-inhibitors and increasing my use of alternative MOAs for the treatment of psoriasis in the near future."
LLY: 81.29 (+0.42)
Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:25AM CDT
Eli Lilly (LLY) announced that the EMA's CHMP issued a positive opinion on olaratumab for the treatment of advanced soft tissue sarcoma (STS).
ANIP: 66.81 (+1.69), LLY: 81.29 (+0.42), CORT: 6.49 (+0.27), PCRX: 37.52 (+0.71)
Research and Markets - Global Insulin Delivery Systems Market 2016-2020 - Key vendors are Novo Nordisk, Sanofi, BD, Eli Lilly & Medtronic
PR Newswire Europe - Sat Sep 17, 6:31AM CDT
DUBLIN, September 2, 2016 /PRNewswire/ --
MDT: 87.82 (+0.68), LLY: 81.29 (+0.42)
Research and Markets - Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating the $150+ Billion Market
PR Newswire Europe - Sat Sep 17, 5:54AM CDT
DUBLIN, August 31, 2016 /PRNewswire/ --
MRK: 63.02 (+0.32), LLY: 81.29 (+0.42)
CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma
PR Newswire - Fri Sep 16, 6:22AM CDT
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the granting of a conditional marketing authorization for olaratumab, in combination with doxorubicin, for the treatment of adults in the European Union (EU) with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and who have not been previously treated with doxorubicin. The CHMP reviewed olaratumab under EMA's accelerated assessment program. If approved, olaratumab will be marketed under the trade name LARTRUVO(TM).
LLY: 81.29 (+0.42)
Boston Mayor Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter, Receive Alzheimer's Readiness Award
PR Newswire - Thu Sep 15, 11:15AM CDT
Boston Mayor Martin J. Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter were recognized today for their efforts to ensure the city of Boston is prepared for the fiscal and social impact of Alzheimer's disease.
LLY: 81.29 (+0.42)
Modality Solutions Announces Partnership with IQPC for the 14th Annual Cold Chain GDP & Temperature Management Logistics Global Forum
PRWeb - Thu Sep 15, 2:49AM CDT
Modality Solutions, LLC, a privately-held company that delivers integrated cold chain management solutions for life sciences and food industries, is pleased to announce they are once again sponsoring and presenting an innovative approach to understanding thermal passive shipper performance at the 14th Annual Cold Chain GDP & Temperature Management Logistics Global Forum. Modality Solutions will be joined by 850 temperature controlled life science leaders, September 26-30 at the Hynes Veterans Memorial Convention Center in Boston, Massachusetts.
LLY: 81.29 (+0.42)
Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career
PR Newswire - Wed Sep 14, 8:30AM CDT
Eli Lilly and Company (NYSE: LLY) today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior vice president, Global Development & Medical Affairs, for Lilly's Oncology business on January 1, 2017. He will succeed Richard Gaynor, M.D., who will retire after a distinguished career at Lilly.
LLY: 81.29 (+0.42)
Elanco's Antibiotic Stewardship Plan Yields Innovation, Scientific Advancements
PR Newswire - Wed Sep 14, 5:00AM CDT
Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), reports on scientific and structural advancements made toward enhancing responsible antibiotic use and bringing new alternatives to decrease the need for shared-class antibiotics in livestock. In an update tracking progress of its 8-Point Antibiotic Stewardship Plan unveiled last year, Elanco announces the following actions:
LLY: 81.29 (+0.42)
2020 Animal Health Market Forecasts: Sanofi, Merck and Co., Eli Lilly and Company & Zoetis Inc. Reviewed
PR Newswire Europe - Wed Sep 14, 1:13AM CDT
PUNE, India, September 14, 2016 /PRNewswire/ --
ZTS: 51.63 (+0.57), MRK: 63.02 (+0.32), LLY: 81.29 (+0.42)
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 8:12AM CDT
Media and political focus on the high prices of drugs have made things difficult for the pharma/biotech sector since the past one year.
ABT: 42.22 (+0.30), BIIB: 314.81 (+2.81), VNDA: 16.62 (+1.06), PFE: 34.15 (-0.13), AMGN: 175.62 (+1.77), AEGR: 2.65 (+0.33), LLY: 81.29 (+0.42), PDLI: 3.35 (-0.01), JNJ: 119.46 (+0.55), GILD: 81.52 (-0.18), AZN: 34.28 (+0.53), MRK: 63.02 (+0.32), SNY: 38.57 (+0.19), NVS: 82.03 (+0.51)
Pharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib
Arpita Dutt - Zacks Investment Research - Fri Sep 09, 7:14AM CDT
The drug pricing controversy and Mylan (MYL) remained in the news this week as well.
AGN: 243.43 (+5.02), NVO: 45.57 (-0.47), MRK: 63.02 (+0.32), MYL: 42.59 (+0.68), LLY: 81.29 (+0.42), BMY: 56.42 (+0.49), SNY: 38.57 (+0.19)
Upgrade Alert for Eli Lilly (LLY)
Comtex SmarTrend(R) - Fri Sep 09, 3:14AM CDT
Eli Lilly (NYSE:LLY) was upgraded from Neutral to Overweight at JP Morgan today. The stock closed yesterday at $79.89 on volume of 4.4 million shares, above average daily volume of 3.5 million. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company's products are sold in countries around the world. Eli Lilly's products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
LLY: 81.29 (+0.42)
